Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer
80
about 8.1 years
18+
Male only
1 site in PA
About this study
Researchers are testing if adaptive stereotactic body radiation therapy (SBRT) with a SIB is safe and effective to treat prostate cancer in men. The trial will assess the safety of this treatment over time, including side effects and quality of life.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive adaptive stereotactic body radiation therapy (SBRT) with a SIB
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Severe (CTCAE grade ≥ 3) treatment-related (possibly, probably or definitely) toxicity occurring within 90 days of treatment.
Secondary: Biochemically progression free survival, Distant metastasis free survival
radiation
Oncology